Analysts expect Dynavax Technologies Co. (NASDAQ:DVAX) to post $820,000.00 in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Dynavax Technologies’ earnings. The highest sales estimate is $1.24 million and the lowest is $400,000.00. Dynavax Technologies posted sales of $150,000.00 during the same quarter last year, which suggests a positive year over year growth rate of 446.7%. The company is expected to issue its next quarterly earnings results on Monday, May 14th.
According to Zacks, analysts expect that Dynavax Technologies will report full-year sales of $15.14 million for the current year, with estimates ranging from $11.19 million to $19.09 million. For the next fiscal year, analysts expect that the firm will report sales of $115.93 million per share, with estimates ranging from $115.41 million to $116.45 million. Zacks Investment Research’s sales averages are an average based on a survey of research firms that cover Dynavax Technologies.
Dynavax Technologies (NASDAQ:DVAX) last released its quarterly earnings results on Thursday, March 8th. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.32). Dynavax Technologies had a negative return on equity of 57.43% and a negative net margin of 29,099.08%. The firm had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.53 million.
DVAX has been the subject of several analyst reports. BidaskClub lowered shares of Dynavax Technologies from a “hold” rating to a “sell” rating in a report on Thursday, January 11th. ValuEngine upgraded shares of Dynavax Technologies from a “sell” rating to a “hold” rating in a report on Tuesday, March 27th. Cowen restated a “buy” rating and set a $30.00 price target on shares of Dynavax Technologies in a report on Wednesday, February 21st. JPMorgan Chase lowered shares of Dynavax Technologies from an “overweight” rating to a “neutral” rating and lowered their price target for the stock from $31.00 to $25.00 in a report on Wednesday, February 14th. Finally, Zacks Investment Research lowered shares of Dynavax Technologies from a “hold” rating to a “sell” rating in a report on Wednesday, January 10th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $24.67.
Dynavax Technologies stock opened at $18.70 on Friday. Dynavax Technologies has a 52-week low of $5.15 and a 52-week high of $24.45. The company has a market cap of $1,239.79, a price-to-earnings ratio of -10.81 and a beta of 0.84.
In other news, insider David F. Novack sold 34,214 shares of Dynavax Technologies stock in a transaction on Tuesday, March 13th. The shares were sold at an average price of $16.52, for a total value of $565,215.28. Following the completion of the sale, the insider now owns 21,613 shares in the company, valued at approximately $357,046.76. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider David F. Novack sold 2,121 shares of Dynavax Technologies stock in a transaction on Friday, March 9th. The shares were sold at an average price of $17.97, for a total transaction of $38,114.37. Following the completion of the sale, the insider now owns 77,192 shares of the company’s stock, valued at approximately $1,387,140.24. The disclosure for this sale can be found here. Insiders sold a total of 52,444 shares of company stock valued at $865,906 in the last quarter. 2.90% of the stock is currently owned by company insiders.
Several large investors have recently added to or reduced their stakes in the company. Legal & General Group Plc increased its stake in shares of Dynavax Technologies by 36.1% in the 3rd quarter. Legal & General Group Plc now owns 17,013 shares of the biopharmaceutical company’s stock valued at $365,000 after acquiring an additional 4,512 shares in the last quarter. American International Group Inc. increased its stake in shares of Dynavax Technologies by 32.7% in the 3rd quarter. American International Group Inc. now owns 40,399 shares of the biopharmaceutical company’s stock valued at $869,000 after acquiring an additional 9,946 shares in the last quarter. Rock Springs Capital Management LP increased its stake in shares of Dynavax Technologies by 6.1% in the 4th quarter. Rock Springs Capital Management LP now owns 175,000 shares of the biopharmaceutical company’s stock valued at $3,273,000 after acquiring an additional 10,000 shares in the last quarter. California State Teachers Retirement System increased its stake in shares of Dynavax Technologies by 12.0% in the 3rd quarter. California State Teachers Retirement System now owns 97,417 shares of the biopharmaceutical company’s stock valued at $2,094,000 after acquiring an additional 10,412 shares in the last quarter. Finally, Fox Run Management L.L.C. bought a new stake in shares of Dynavax Technologies in the 4th quarter valued at $257,000. Institutional investors own 71.23% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Brokerages Expect Dynavax Technologies Co. (DVAX) Will Post Quarterly Sales of $820,000.00” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another website, it was illegally stolen and reposted in violation of United States and international copyright law. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/04/20/brokerages-expect-dynavax-technologies-co-dvax-will-post-quarterly-sales-of-820000-00.html.
About Dynavax Technologies
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company's lead product candidates include HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of the virus in adults age 18 years and older; SD-101, a cancer immunotherapy that is in Phase 2 clinical studies; and DV281, an investigational TLR9 agonist for the treatment of non-small cell lung cancer.
Get a free copy of the Zacks research report on Dynavax Technologies (DVAX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.